drugset / Trial / NCT05770180
Phase II Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell)
RandomizedParallel-groupDouble-blindPrevention
Summary
A single-center, randomized, double-blind, controlled clinical trial to evaluate the safety and immunogenicity of booster vaccination of Recombinant COVID-19 variant vaccine (Sf9 cell) in healthy people aged 18 years and older after completing 2 or 3 doses of novel coronavirus inactivated vaccine (Vero cells)
Timeline
- Start
- 2023-03-30
- Primary completion
- 2023-07-30
- Completion
- 2024-04-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Recombinant COVID-19 Vaccine (Sf9 Cell) | Vaccine | — | — |
| Subject | Recombinant COVID-19 Variant Vaccine (Sf9 Cell) | Vaccine | — | — |
| Comparator | Recombinant COVID-19 vaccine(CHO cell) | Vaccine | — | — |